Skip to main content
Top
Published in: Journal of Cancer Education 4/2019

01-08-2019

Quality of Life in Patients with Non-melanoma Skin Cancer: Implications for Healthcare Education Services and Supports

Authors: Robabeh Abedini, Maryam Nasimi, Pedram Noormohammad Pour, Atie Moghtadaie, Hamid Reza Tohidinik

Published in: Journal of Cancer Education | Issue 4/2019

Login to get access

Abstract

Non-melanoma skin cancer (NMSC) is the most prevalent type of cancer among Caucasian populations worldwide. The purpose of this work was to measure quality of life (QOL) of the patients with diagnosis of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) who were referred to our cancer clinic. During 1 year, 95 patients were selected and asked to complete Dermatology Life Quality Index (DLQI) questionnaires. Ninety-five patients with NMSC (74 men and 21 women) with mean age of 64.6 ± 12.5 participated in this cross-sectional study. From 95 patients, 75 had BCC, 15 had SCC, and 5 patients had both SCC and BCC. The total DLQI scores of the all participants were between 0 and 16; the mean was 4.1 ± 4.25 and median was 2. Variables which were associated with impaired QOL were marital status (P = 0.03) and tumor location (P = 0.02). By using general dermatology QOL questionnaire, it had been demonstrated that patients with NMSC faced with minimal QOL impairment; also, this handicap was more pronounced in younger patients and singles and patients with tumors located in exposed areas. Our findings demonstrated a need to educate our patients to improve patients’ knowledge about different aspects of disease.
Literature
2.
go back to reference Jung GW, Metelitsa AI, Dover DC, Salopek TG (2010) Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007. Br J Dermatol 163:146–154PubMed Jung GW, Metelitsa AI, Dover DC, Salopek TG (2010) Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007. Br J Dermatol 163:146–154PubMed
3.
go back to reference Telfer NR, Colver GB, Morton CA (2008) Guidelines for the management of basal cell carcinoma. Br J Dermatol 159:35–48CrossRefPubMed Telfer NR, Colver GB, Morton CA (2008) Guidelines for the management of basal cell carcinoma. Br J Dermatol 159:35–48CrossRefPubMed
4.
go back to reference Chren MM, Sahay AP, Bertenthal DS, Sen S, Seth Landefeld C (2007) Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 127:1351–1357CrossRefPubMed Chren MM, Sahay AP, Bertenthal DS, Sen S, Seth Landefeld C (2007) Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 127:1351–1357CrossRefPubMed
5.
go back to reference Ernst J, Götze H, Brähler E et al (2012) Quality of life of parents diagnosed with cancer: change over time and influencing factors. Eur J Cancer Care (Engl) 21:535–541CrossRef Ernst J, Götze H, Brähler E et al (2012) Quality of life of parents diagnosed with cancer: change over time and influencing factors. Eur J Cancer Care (Engl) 21:535–541CrossRef
6.
go back to reference Meyer AA, Hwang M, Farasatpour M et al (2013) Metastatic breast cancer in patients with schizophrenia. Mol Clin Oncol 1:359–364CrossRefPubMed Meyer AA, Hwang M, Farasatpour M et al (2013) Metastatic breast cancer in patients with schizophrenia. Mol Clin Oncol 1:359–364CrossRefPubMed
7.
go back to reference Sellick SM, Crooks DL (1999) Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psychooncology 8:315–333CrossRefPubMed Sellick SM, Crooks DL (1999) Depression and cancer: an appraisal of the literature for prevalence, detection, and practice guideline development for psychological interventions. Psychooncology 8:315–333CrossRefPubMed
8.
go back to reference Gaulin C, Sebaratnam DF, Fernández-Peñas P (2015) Quality of life in non-melanoma skin cancer. Australas J Dermatol 56:70–76CrossRefPubMed Gaulin C, Sebaratnam DF, Fernández-Peñas P (2015) Quality of life in non-melanoma skin cancer. Australas J Dermatol 56:70–76CrossRefPubMed
9.
go back to reference Abedini R, Nasimi M, Nourmohammad Pour P, Etesami I, Al-Asiri S, Tohidinik HR (2017) Skin cancer awareness and sun protection behavior before and following treatment among skin cancer-treated patients. J Cancer Educ 15:1–6 Abedini R, Nasimi M, Nourmohammad Pour P, Etesami I, Al-Asiri S, Tohidinik HR (2017) Skin cancer awareness and sun protection behavior before and following treatment among skin cancer-treated patients. J Cancer Educ 15:1–6
10.
go back to reference Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216CrossRefPubMed Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216CrossRefPubMed
11.
go back to reference Czajkowska Z, Radiotis G, Roberts N, Körner A (2013) Cognitive adaptation to nonmelanoma skin cancer. J Psychosoc Oncol 31:377–392CrossRefPubMed Czajkowska Z, Radiotis G, Roberts N, Körner A (2013) Cognitive adaptation to nonmelanoma skin cancer. J Psychosoc Oncol 31:377–392CrossRefPubMed
12.
go back to reference Roberts N, Czajkowska Z, Radiotis G, Körner A (2013) Distress and coping strategies among patients with skin cancer. J Clin Psychol Med Settings 20:209–214CrossRefPubMed Roberts N, Czajkowska Z, Radiotis G, Körner A (2013) Distress and coping strategies among patients with skin cancer. J Clin Psychol Med Settings 20:209–214CrossRefPubMed
13.
go back to reference Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY (2004) DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 4:8CrossRefPubMedPubMedCentral Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY (2004) DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol 4:8CrossRefPubMedPubMedCentral
14.
go back to reference Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB (2006) Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 8:314–318CrossRefPubMedPubMedCentral Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB (2006) Validation of a quality-of-life instrument for patients with nonmelanoma skin cancer. Arch Facial Plast Surg 8:314–318CrossRefPubMedPubMedCentral
15.
go back to reference Maciel PC, Veiga-Filho J, Carvalho MP et al (2014) Quality of life and self-esteem in patients submitted to surgical treatment of skin carcinomas: long-term results. An Bras Dermatol 89:594–598CrossRefPubMedPubMedCentral Maciel PC, Veiga-Filho J, Carvalho MP et al (2014) Quality of life and self-esteem in patients submitted to surgical treatment of skin carcinomas: long-term results. An Bras Dermatol 89:594–598CrossRefPubMedPubMedCentral
16.
go back to reference Carvalho MP, Oliveira Filho RS, Gomes HC et al (2007) Auto-estima em pacientes com carcinomas de pele. Rev Col Bras Cir 34(6):361–366CrossRef Carvalho MP, Oliveira Filho RS, Gomes HC et al (2007) Auto-estima em pacientes com carcinomas de pele. Rev Col Bras Cir 34(6):361–366CrossRef
17.
go back to reference Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM (2011) Quality of life in health care of non-melanoma skin cancer—results of a pilot study. J Dtsch Dermatol Ges 9:129–135PubMed Steinbauer J, Koller M, Kohl E, Karrer S, Landthaler M, Szeimies RM (2011) Quality of life in health care of non-melanoma skin cancer—results of a pilot study. J Dtsch Dermatol Ges 9:129–135PubMed
18.
go back to reference Blackford S, Roberts D, Salek MS, Finlay A (1996) Basal cell carcinomas cause little handicap. Qual Life Res 5:191–194CrossRefPubMed Blackford S, Roberts D, Salek MS, Finlay A (1996) Basal cell carcinomas cause little handicap. Qual Life Res 5:191–194CrossRefPubMed
19.
go back to reference Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB (2004) Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 30:525–529PubMed Rhee JS, Matthews BA, Neuburg M, Smith TL, Burzynski M, Nattinger AB (2004) Skin cancer and quality of life: assessment with the Dermatology Life Quality Index. Dermatol Surg 30:525–529PubMed
20.
go back to reference Nunes DH, FrÖde TS (2013) Quality of life in basal cell carcinoma patients in Brazil: a pilot cross sectional study. Dermatol Surg 39:620–626CrossRefPubMed Nunes DH, FrÖde TS (2013) Quality of life in basal cell carcinoma patients in Brazil: a pilot cross sectional study. Dermatol Surg 39:620–626CrossRefPubMed
21.
go back to reference Rhee JS, Matthews BA, Neuburg M, Burzynski M, Nattinger AB (2005) Creation of a quality of life instrument for non-melanoma skin cancer patients. Laryngoscope 115:1178–1185CrossRefPubMedPubMedCentral Rhee JS, Matthews BA, Neuburg M, Burzynski M, Nattinger AB (2005) Creation of a quality of life instrument for non-melanoma skin cancer patients. Laryngoscope 115:1178–1185CrossRefPubMedPubMedCentral
22.
go back to reference Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB (2006) Validation of a quality of-life instrument for patients with non-melanoma skin cancer. Arch Facial Plast Surg 8:314–318CrossRefPubMedPubMedCentral Rhee JS, Matthews BA, Neuburg M, Logan BR, Burzynski M, Nattinger AB (2006) Validation of a quality of-life instrument for patients with non-melanoma skin cancer. Arch Facial Plast Surg 8:314–318CrossRefPubMedPubMedCentral
Metadata
Title
Quality of Life in Patients with Non-melanoma Skin Cancer: Implications for Healthcare Education Services and Supports
Authors
Robabeh Abedini
Maryam Nasimi
Pedram Noormohammad Pour
Atie Moghtadaie
Hamid Reza Tohidinik
Publication date
01-08-2019
Publisher
Springer US
Published in
Journal of Cancer Education / Issue 4/2019
Print ISSN: 0885-8195
Electronic ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-018-1368-y

Other articles of this Issue 4/2019

Journal of Cancer Education 4/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine